CAR T-Cell therapy saves leukemia patient in China

Share This Post

Feb 2022: A 12-year-old girl from southwest China’s Chongqing Municipality was saved by an unconventional therapy instead of chemotherapy or hematopoietic stem cell transplantation.
Yi Mengdie has a seven-month medical history and has been given first-aid six times within a day due to the deterioration of her disease, according to local media She has acute lymphoblastic leukaemia (ALL), a type of cancer in which the bone marrow produces too many immature white blood cells.
Yi’s fever had gone away and her different indexes had returned to normal when reporter saw her in the city’s Southwest Hospital in October after taking a new therapy called CAR-T cell therapy on September 18.

According to the same study, 25 individuals were treated in the hospital with this therapy.

CAR-T cells and TCR T cells have specific receptors on their surfaces that have been designed. They’re then expanded in the lab before being given back to the patient. /Photo courtesy of the National Cancer Institute

According to the National Cancer Institute (NCI), the US government’s premier office for cancer research, T cells are commonly referred to as the immune system’s workhorses because of their vital function in coordinating the immune response and killing cells infected by infections.

Drawing blood from patients and extracting T cells is required for CAR-T cell treatment. The T cells are then genetically altered to develop receptors on their surface called chimeric antigen receptors (CARs), which allow the T cells to recognise and adhere to a specific protein, or antigen, on tumour cells, using a disarmed virus, according to the National Cancer Institute.

After the T cells have been designed to express the antigen-specific CAR, they are “expanded” into hundreds of millions in the laboratory.

If all goes according to plan, the designed cells will multiply in the patient’s body and, with the help of their engineered receptor, will recognise and kill cancer cells with the antigen on their surfaces, according to the NCI.

Renier J. Brentjens, an early leader in the CAR-T cell field, described CAR-T cells as “offering patients a living medication.”

Apply for CAR T-Cell therapy

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form